Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aerovate Therapeutics (AVTE)
NASDAQ:AVTE
Aerovate Therapeutics (AVTE) Stock Price & Analysis
80 Followers
AVTE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$9.41 - $32.42
Previous Close$19.14
Volume246.86K
Average Volume (3M)152.58K
Market Cap
$550.03M
Enterprise Value$428.27M
Total Cash (Recent Filing)$122.44M
Total Debt (Recent Filing)$675.00K
Price to Earnings (P/E)-6.7
Beta0.86
Next Earnings
Aug 12, 2024EPS Estimate
-$0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.87
Shares Outstanding27,862,961
10 Day Avg. Volume128,436
30 Day Avg. Volume152,584
Standard Deviation0.29
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.05
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.38
Forecast
1Y Price Target
$47.75Price Target Upside147.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Aerovate Therapeutics News
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressAerovate has generated positive data in a Phase I study in healthy volunteers, demonstrating that the inhaled form of imatinib resulted in equivalent or higher lung exposures with lower systemic exposure compared to the oral therapy.
Financial StabilityThe company has cash of $99.3MM providing runway into 2026E.
Market OpportunityAnalyst expectations for the AV-101 drug include at least a 20% reduction in pulmonary vascular resistance and a better adverse event profile compared to oral imatinib, indicating a promising future for the drug.
Bears Say
Clinical Trial OutcomesShould the therapy not achieve a PVR reduction of 20% with a 6MWD markedly below 20 meters, the stock could be down substantially.
Drug Efficacy And SafetyIMPAHCT fails to meet the bar for a clinically meaningful efficacy or shows unexpected safety signals.
Market Acceptance And Investor SentimentDespite the potential, many investors remain skeptical of AVTE due to past experiences with similar drugs like seralutinib.
---
Ownership Overview
48.70% Insiders
5.59% Mutual Funds
11.25% Other Institutional Investors
34.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVTE FAQ
What was Aerovate Therapeutics’s price range in the past 12 months?
Aerovate Therapeutics lowest stock price was $9.41 and its highest was $32.41 in the past 12 months.
What is Aerovate Therapeutics’s market cap?
Currently, no data Available
When is Aerovate Therapeutics’s upcoming earnings report date?
Aerovate Therapeutics’s upcoming earnings report date is Aug 12, 2024 which is in 89 days.
How were Aerovate Therapeutics’s earnings last quarter?
Aerovate Therapeutics released its earnings results on May 13, 2024. The company reported -$0.83 earnings per share for the quarter, missing the consensus estimate of -$0.765 by -$0.065.
Is Aerovate Therapeutics overvalued?
According to Wall Street analysts Aerovate Therapeutics’s price is currently Undervalued.
Does Aerovate Therapeutics pay dividends?
Aerovate Therapeutics does not currently pay dividends.
What is Aerovate Therapeutics’s EPS estimate?
Aerovate Therapeutics’s EPS estimate is -$0.8.
How many shares outstanding does Aerovate Therapeutics have?
Aerovate Therapeutics has 28,737,381 shares outstanding.
What happened to Aerovate Therapeutics’s price movement after its last earnings report?
Aerovate Therapeutics reported an EPS of -$0.83 in its last earnings report, missing expectations of -$0.765. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Aerovate Therapeutics?
Among the largest hedge funds holding Aerovate Therapeutics’s share is RA Capital Management. It holds Aerovate Therapeutics’s shares valued at 187M.
---
Aerovate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.75 (147.67% Upside)
$47.75 (147.67% Upside)
Blogger Sentiment
Bullish
AVTE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 405.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $334.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.33%
12-Months-Change
Fundamentals
Return on Equity
-63.95%
Trailing 12-Months
Asset Growth
-5.83%
Trailing 12-Months
Company Description
Aerovate Therapeutics
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.
---
AVTE Stock 12 Month Forecast
Average Price Target
$47.75
▲(147.67% Upside)
Technical Analysis
Best Analysts Covering AVTE
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+29.13%
reiterated a buy rating 2 months ago
Copying Julian Harrison's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +29.13% per trade.
---